Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price traded down 8.2% during mid-day trading on Monday . The company traded as low as GBX 16 and last traded at GBX 16.89. Approximately 4,823,857 shares changed hands during trading, an increase of 146% from the average session volume of 1,962,216 shares. The stock had previously closed at GBX 18.40.
Scancell Stock Performance
The business has a 50 day moving average price of GBX 19.41 and a two-hundred day moving average price of GBX 14.58. The stock has a market cap of £175.28 million, a P/E ratio of -30.71 and a beta of 0.71. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
See Also
- Five stocks we like better than Scancell
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
